ScreenerHero

LYRA Lyra Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · lyratherapeutics.com
0.2000USD0.00%Mkt Cap: 354976 $P/E: —

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap354.98K USD
Enterprise Value14.70M USD
Revenue (TTM)398.00K USD
Gross Profit-608.00K USD
Net Income (TTM)-28.92M USD
Revenue/Share0.26 USD
Last Price0.2000 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees27
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.19
PEG—
EV/EBITDA-0.51
EV/Revenue36.94
P/S0.85
P/B-0.03
EPS (TTM)-18.62
EPS (Forward)-0.99
52W Range
0.00042% of range8.748
52W High8.748 USD
52W Low0.0004 USD
Profitability
Gross Margin-152.76%
Oper. Margin-98728.57%
EBITDA Margin0.00%
Profit Margin-7266.08%
ROE269.84%
ROA-80.09%
Growth
Revenue Growth-96.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.86M USD
CapEx (TTM)116.00K USD
FCF Margin-4404.43%
FCF Yield-4938.26%
Net Debt14.37M USD
Net Debt/EBITDA-0.49
Balance Sheet
Debt/Equity-2.82
Current Ratio1.71
Quick Ratio1.67
Book Value/Sh-6.04 USD
Cash/Share8.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMay 28, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.77M
Float440.19K
Insiders0.62%
Institutions6.64%
Short Interest
Short Ratio0.7d
Short % Float2.82%
Short % Out.2.40%
Shares Short42.62K
Short (prev mo.)56.49K
Technical
SMA 500.2122 (-5.8%)
SMA 2000.8701 (-77.0%)
Beta0.50
S&P 52W Chg16.45%
Avg Vol (30d)1.07K
Avg Vol (10d)650
Technical Indicators
RSI (14)45.4
MACD-0.0368
MACD Signal-0.0552
MACD Hist.+0.0184
BB Upper0.3323 USD
BB Middle0.1578 USD
BB Lower-0.0167 USD
BB Width221.20%
ATR (14)0.0793 USD
Vol Ratio (20d)0.00x